Reference

Dry powder for inhalation comprising a formoterol salt and ciclesonide

Dry powder for inhalation comprising a formoterol salt and ciclesonide.Several substances are used for example 3458-28-4 and 200815-49-2 which are their cas registry numbers. Heaton, Zoe; Wayland, Ruth Margaret (Aventis Pharma Limited, UK). PCT Int. Appl. WO 2005004853 A1 20 Jan 2005, 44 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K009-72. ICS: A61K031-167; A61K031-573. APPLICATION: WO 2004-GB2953 8 Jul 2004. PRIORITY: GB 2003-15889 8 Jul 2003. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) A stable pharmaceutical product is provided comprising (i) a dry powder inhalation device, (ii) a pharmaceutical compn. contg. R,R-formoterol L-tartrate salt, in particular cryst. R,R-formoterol L-tartrate, and ciclesonide, (iii) an effective amt. of a sorbent material, and (d) a sealed package vol. in which the device, the sorbent material and the pharmaceutical compn. are situated. The sorbent material, e.g., an activated clay, alumina or silica, is housed within the dry powder inhalation device comprising polyacetal material that leaches formaldehyde capable of causing degrdn. of R,R-formoterol L-tartrate. .

Taking Advantage of Polymorphism To Effect an Impurity Removal: Development of a Thermodynamic Crystal Form of (R,R)-Formoterol Tartrate

Taking Advantage of Polymorphism To Effect an Impurity Removal: Development of a Thermodynamic Crystal Form of (R,R)-Formoterol Tartrate. Tanoury, Gerald J.; Hett, Robert; Kessler, Donald W.; Wald, Stephen A.; Senanayake, Chris H. (Chemical Research and Development, Sepracor Inc., Marlborough, MA 01752, USA). Organic Process Research & Development, 6(6), 855-862 (English) 2002 American Chemical Society. CODEN: OPRDFK.In this article, certain chemicals are used. One of their cas registry numbers is 200815-49-2 ISSN: 1083-6160. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) The development and large-scale implementation of a novel technol.There are some reagents like 200815-49-2 is used in this study. utilizing polymorphic interconversion and cryst. intermediate formation of (R,R)-formoterol L-tartrate (I) as a tool for the removal of impurities from the final product and generation of the most thermodynamically stable crystal form is reported. The crude product was generated by pptn. of the free base as the L-tartrate salt in a unique polymorphic form, form B. Warming the resultant slurry effected the formation of a partially hydrated stable cryst. intermediate, form C, with a concomitant decrease in the impurity levels in the solid. Isolation and recrystn. of form C provided I in the thermodynamically most stable polymorph, form A. ..